Although local inflammation and activated NF-κB signaling have been associated with TMZ treatment and resistance in both GBM and melanoma [13,34,35], the involvement of NLRP or NLRP inflammasomes has not been nowadays reported in the development of drug resistance in any cells. The gene discussed is NFKB1; the disease is glioblastoma.